Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 2Thoracic 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Stomach Neoplasms 1Skin Neoplasms 1Neoplasm Recurrence, Local 1Neoplasm Metastasis 1Lung Neoplasms 1Liver Neoplasms 1Kidney Neoplasms 1Esophageal Neoplasms 1Colorectal Neoplasms 1Carcinoma, Hepatocellular 1Breast Neoplasms 1

Interventions

pembrolizumab 3Nivolumab 3Ipilimumab 2Interleukin-2 2Drug Therapy 2Biopsy 2pertuzumab 1osimertinib 1montanide ISA 51 1liposomal doxorubicin 1cobimetinib 1brodalumab 1atezolizumab 1Trastuzumab 1Tissue Banks 1Surveys and Questionnaires 1Standard of Care 1Specimen Handling 1Radiotherapy 1Radiosurgery 1Quality of Life 1Psychiatric Rehabilitation 1Poly I-C 1Photochemotherapy 1Patient Reported Outcome Measures 1Paclitaxel 1Oxaliplatin 1Observation 1Molecular Diagnostic Techniques 1Mass Screening 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Skin Neoplasms × Poly I-C × Gastrointestinal × Clear all
NCT00094003 2005-11-11

Study of NS-9 in Patients With Liver Metastases

NS Pharma, Inc.

Phase 1 Completed
20 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Esophageal Neoplasms, Kidney Neoplasms, Liver Neoplasms, Lung Neoplasms, Neoplasm Metastasis, Neoplasm Recurrence, Local, Skin Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡